Evoke Wealth LLC Has $403,000 Stock Position in Kenvue Inc. (NYSE:KVUE)

Evoke Wealth LLC lessened its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,863 shares of the company's stock after selling 12,329 shares during the period. Evoke Wealth LLC's holdings in Kenvue were worth $403,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after acquiring an additional 3,075,019 shares during the last quarter. State Street Corp boosted its holdings in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Kenvue by 0.9% during the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock worth $1,029,810,000 after purchasing an additional 399,846 shares during the period. Finally, Harris Associates L P lifted its position in shares of Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock worth $727,658,000 after buying an additional 2,186,114 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KVUE shares. Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. Piper Sandler upped their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. UBS Group dropped their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Evercore ISI started coverage on Kenvue in a research report on Monday. They set an "in-line" rating and a $25.00 price objective for the company. Finally, Barclays dropped their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $23.85.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.07 during trading hours on Monday, hitting $23.38. 13,187,062 shares of the company's stock traded hands, compared to its average volume of 16,157,921. The company's fifty day simple moving average is $22.08 and its two-hundred day simple moving average is $22.43. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 44.10, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.